Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”

Andrew G. Chapple; Peter F. Thall

doi:10.1111/biom.12991

Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”

Biostatistics

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	389-391
Number of pages	3
Journal	Biometrics
Volume	75
Issue number	2
DOIs	https://doi.org/10.1111/biom.12991
State	Published - 2019

ASJC Scopus subject areas

Statistics and Probability
General Biochemistry, Genetics and Molecular Biology
General Immunology and Microbiology
General Agricultural and Biological Sciences
Applied Mathematics

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1111/biom.12991

Cite this

@article{eada5efb33a046079a0a1752e77c913b,

title = "Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”",

author = "Chapple, {Andrew G.} and Thall, {Peter F.}",

year = "2019",

doi = "10.1111/biom.12991",

language = "English (US)",

volume = "75",

pages = "389--391",

journal = "Biometrics",

issn = "0006-341X",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”

AU - Chapple, Andrew G.

AU - Thall, Peter F.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85071554988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071554988&partnerID=8YFLogxK

U2 - 10.1111/biom.12991

DO - 10.1111/biom.12991

M3 - Article

C2 - 31245839

AN - SCOPUS:85071554988

SN - 0006-341X

VL - 75

SP - 389

EP - 391

JO - Biometrics

JF - Biometrics

IS - 2

ER -

Rejoinder to “A hybrid phase I-II/III clinical trial design allowing dose reoptimization in phase III”

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Cite this